title: Does ramucirumab deserve a second chance for liver cancer?
authors.affiliation: Barcelona Clinic Liver Cancer (BCLC) group, Liver Unit, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain. Electronic address: aforner@clinic.ub.es.
authors.forename: Alejandro
authors.initials: A
authors.lastname: Forner
authors.affiliation: Barcelona Clinic Liver Cancer (BCLC) group, Liver Unit, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain.
authors.forename: María
authors.initials: M
authors.lastname: Reig
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D010671:Phenylurea Compounds; D009536:Niacinamide